CHAPEL HILL, N.C., April 28 /PRNewswire/ -- The biopharma mega-mergers that grabbed headlines last year - Roche + Genentech, Pfizer + Wyeth and Merck + Schering-Plough - are now in the critical post-integration period and the acquiring companies are finding out how well they planned and executed their integration plans. It's too early for final verdicts, but clearly one M&A issue that continues to create problems for the industry is the integration of corporate cultures.
A Best Practices, LLC study found while corporate culture was rated as a highly important risk-assessment factor for a successful integration, cultural assessments were rated as a less effective pre-integration planning activity due to accuracy. Experienced integration leaders develop specific processes and approaches to assess the culture of M&A targets and then continuously assess and monitor to ensure the cultures integrate along with operations, according to our report "M&A Integration Excellence: What Bio-Pharma Companies Need to Know."
To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr997.htm.
Understanding and managing cultural issues is just one of the topics addressed in the 107-page report, which utilizes benchmark metrics and executive insights to assess current trends and future directions of bio-pharmaceutical M&A activity. The study had 26 organizations participate, including such influential companies as Pfizer, Eli Lilly, Johnson & Johnson and Abbott.
Other key topic areas in the research include:
- Structure for Integration
- Pre-Integration Planning Activities
- Integration Risk Management
- Integration Functional Excellence
- Communications Excellence
- Understanding & Managing Cultural Issues
- Post-Deal Closure Integration Activities
- Trends in M&A Integration
The pace of merger and acquisition activity in the biopharma sector remains steady as organizations continue to seek external opportunities to grow their pipelines. This data-rich report addresses key M&A issues and identifies proven practices and key success factors in the merger & acquisition integration process among pharmaceutical and biotechnology companies.
The key points this study addresses are:
- What are the keys to successful M&A integration planning?
- What structure, processes and best practices lead to M&A integration excellence?
- What are the key risk factors to assess and manage in the M&A integration process?
- How is success of the M&A integration function best measured and represented?
- What are the critical success factors and pitfalls in the integration process?
For more information on this report, contact Jeff Zimmer at [email protected] or (919) 767-9180. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr997.htm.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.
SOURCE Best Practices, LLC